KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Progyny (PGNY) Cash & Equivalents (2018 - 2025)

Progyny (PGNY) has disclosed Cash & Equivalents for 8 consecutive years, with $112.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 30.85% to $112.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $112.2 million through Dec 2025, down 30.85% year-over-year, with the annual reading at $112.2 million for FY2025, 30.85% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $112.2 million at Progyny, down from $134.0 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $170.6 million in Q2 2023, with the low at $29.8 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $104.1 million, with a median of $103.3 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents plummeted 67.46% in 2021, then skyrocketed 300.09% in 2023.
  • Over 5 years, Cash & Equivalents stood at $91.4 million in 2021, then soared by 31.36% to $120.1 million in 2022, then fell by 18.97% to $97.3 million in 2023, then surged by 66.82% to $162.3 million in 2024, then tumbled by 30.85% to $112.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $112.2 million, $134.0 million, and $132.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.